CONMED Corporation (CNMD)

NYSE: CNMD · Real-Time Price · USD
43.20
-1.81 (-4.02%)
Jul 17, 2026, 4:00 PM EDT - Market closed
Market Cap1.30B -15.8%
Revenue (ttm)1.37B +4.1%
Net Income54.85M -53.8%
EPS1.77 -53.6%
Shares Out 30.11M
PE Ratio24.41
Forward PE9.75
Dividend$0.20 (0.46%)
Ex-Dividend DateSep 15, 2025
Volume504,917
Open44.76
Previous Close45.01
Day's Range42.65 - 45.00
52-Week Range31.44 - 56.64
Beta0.93
AnalystsHold
Price Target39.00 (-9.72%)
Earnings DateJul 29, 2026

About CNMD

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems an... [Read more]

Sector Healthcare
IPO Date Jul 23, 1987
Employees 3,900
Stock Exchange NYSE
Ticker Symbol CNMD
Full Company Profile

Financial Performance

In 2025, CONMED's revenue was $1.37 billion, an increase of 5.18% compared to the previous year's $1.31 billion. Earnings were $47.06 million, a decrease of -64.47%.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for CNMD stock is "Hold." The 12-month stock price target is $39.0, which is a decrease of -9.72% from the latest price.

Price Target
$39.0
(-9.72% downside)
Analyst Consensus: Hold
Stock Forecasts

News

Conmed offers could be in $46-$53 per share range, says Needham

Needham keeps a Hold rating on Conmed (CNMD) after Bloomberg reported the company has been exploring a possible sale. A sale makes sense given Conmed’s mid-single digit growth, “strong recurring…

Other symbols: ZBH
6 days ago - TheFly

Conmed could be more attractive to financial than strategic buyer, says JPMorgan

JPMorgan notes that Bloomberg reported last Friday that Conmed (CNMD) was considering selling the company after receiving interest from private equity firms. While “hopeful” that Conmed is on an upwar...

6 days ago - TheFly

Wells finds Conmed sale report ‘little surprising’ after refinance

Wells Fargo keeps an Equal Weight rating on Conmed (CNMD) with a $39 price target after Bloomberg reported the company is exploring a potential sale amid takeover interest from private…

6 days ago - TheFly

Conmed initiated with a Market Perform at BMO Capital

BMO Capital initiated coverage of Conmed (CNMD) with a Market Perform rating and $36 price target Conmed boasts three compelling and underpenetrated growth platforms in AirSeal, Buffalo Filter, and Bi...

11 days ago - TheFly

CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The ...

17 days ago - Business Wire

Conmed downgraded to Underperform from Neutral at BofA

BofA analyst Travis Steed downgraded Conmed (CNMD) to Underperform from Neutral with an unchanged price target of $40. When dollars come back into medtech, the firm thinks they will gravitate…

20 days ago - TheFly

Conmed names John Gallagher as new CFO

CONMED (CNMD) “announced the appointment of John E. Gallagher as Chief Financial Officer, effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory…

4 weeks ago - TheFly

CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer (“CFO”), effective July 15, 2026. Mr. Gallagher succeeds T...

4 weeks ago - Business Wire

Conmed appoints Martin, Mirviss to its Board of Directors

Conmed (CNMD) announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors, effective July 1, 2026. Martin will serve as a member of the Audit Committee…

2 months ago - TheFly

CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin ...

2 months ago - Business Wire

CONMED Transcript: AGM 2026

The meeting confirmed proper notice and quorum, recognized a retiring Board member, and presented three proposals: Director elections, executive compensation, and auditor ratification. All proposals passed by majority vote, with final results to be filed on Form 8-K.

2 months ago - Transcripts

Conmed price target lowered to $40 from $52 at BofA

BofA lowered the firm’s price target on Conmed (CNMD) to $40 from $52 and keeps a Neutral rating on the shares. After having hosted 34 medtech companies last week in…

2 months ago - TheFly

Conmed price target lowered to $40 from $43 at JPMorgan

JPMorgan lowered the firm’s price target on Conmed (CNMD) to $40 from $43 and keeps a Neutral rating on the shares.

2 months ago - TheFly

Conmed reports Q1 EPS 89c, consensus 82c

Reports Q1 revenue $317.0M, consensus $310.6M. “Our 2025 momentum continued in the first quarter as we delivered revenue and adjusted earnings ahead of our expectations,” said Patrick J. Beyer, CONMED...

2 months ago - TheFly

Conmed backs FY26 EPS view of $4.30-$4.45, consensus $4.45

Narrows FY26 revenue view to $1.35B-$1.375B from $1.345B-$1.375B, consensus $1.36B.

2 months ago - TheFly

CONMED Earnings Call Transcript: Q1 2026

Q1 2026 saw organic sales growth and margin improvement, driven by orthopedics and key platforms, despite a GI product line exit and higher interest expense. Full-year guidance was raised for organic growth, with EPS guidance maintained.

2 months ago - Transcripts

CONMED Earnings release: Q1 2026

CONMED released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.

2 months ago - Filings

CONMED Slides: Q1 2026

CONMED has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.

2 months ago - Filings

CONMED Quarterly report: Q1 2026

CONMED has published its Q1 2026 quarterly earnings report on April 29, 2026.

2 months ago - Filings

CONMED Corporation Announces First Quarter 2026 Financial Results

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Sales of $317.0 million decrea...

2 months ago - Business Wire

CONMED Proxy statement: Proxy filing

CONMED filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.

3 months ago - Filings

CONMED Proxy statement: Proxy filing

CONMED filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.

3 months ago - Filings

CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2026 after the market close on Wednesday, April 29, 2026. The ...

3 months ago - Business Wire

Conmed assumed with an Equal Weight at Wells Fargo

Wells Fargo initiated coverage of assumed with an Equal Weight rating and $42 price target The firm is maintaining the current rating, price target and estimates.

4 months ago - TheFly

Conmed downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler analyst Matt O’Brien downgraded Conmed (CNMD) to Neutral from Overweight with a price target of $39, down from $55. The company’s AirSeal “did not completely implode” after Intuitive…

Other symbols: ISRG
4 months ago - TheFly